It took just days for Pfizer and Moderna to design an effective mRNA vaccine against COVID-19 a breathtaking display of the power of this state-of-the-art mRNA technology.
By contrast it took years to design the first effective antiviral drugs against COVID-19, paxlovid and molnupiravir a dismal display of how very yesteryear drug development is.
The only reason these drugs appeared in the clinic within two years of the COVID-19 outbreak rather than ten was because they were salvaged from existing pipelines: paxlovid from a compound targeted against the SARS virus of 2002 and molnupiravir from a compound to target influenza. The normal timeframe of drug development is usually greater than ten years.
Its slow because it involves screening libraries for promising compounds and tweaking their chemistry to turn them into well-behaved drugs years of work before they can even begin to be tested in clinical trials.
Now, by taking a leaf from the mRNA vaccine playbook, that first phase of antiviral drug development the design might become lightning fast.
Last July Mohammed Fareh, a cancer researcher at Melbournes Peter MacCallum Cancer Institute (the Peter Mac) and Sharon Lewin, director of the Peter Doherty Institute, delivered a proof of concept. They made an RNA-based drug that killed SARS-CoV-2 in the culture dish all within a few weeks.
It could be a gamechanger, believes Lewin.
The big question is how to turn it into a treatment, says Melanie Ott, director of the Gladstone Institute of Virology in San Francisco, who was not involved in the research. Nevertheless, she shares the excitement. There is no shortcut when it comes to classical drug chemistry, so this is an opportunity to rethink our approach.
If the vision pans out, this could mark the dawn of an era where we beat viruses at their own evolutionary game. Designer drugs could be deployed within weeks to demolish new SARS-CoV-2 variants and other emerging viruses.
Prior to the pandemic, Farehs day job didnt revolve around shifty viruses but shifty cancers. Some cancer patients show an initial response to a drug. But within months the cancer cells evolve survival strategies, such as learning how to spit out toxic drugs, and resume their unbridled growth.
A diverse arsenal of weapons is needed to tackle these evaders.
In 2017, Feng Zhang at the Broad Institute in Massachusetts found such an arsenal: CRISPR-Cas13. Like CRISPR-Cas9, it is a customisable weapons system that bacteria use to defend themselves from even tinier invaders: the virus-like bacteriophage.
Because it can selectively snip DNA, scientists adapted CRISPR-Cas9 to edit the DNA of plants, animals and even people. Jennifer Doudna and Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for those efforts, but Zhang was also a pioneer. Returning to fossick around the bacterial arsenal, he found another tool, CRISPR-Cas13, lurking in a species called Leptotrichia wadei.
But while Cas9 targets DNA, Cas13 targets RNA.
That opened up a new universe of possibilities. You wouldnt use Cas9 as a drug because you dont want to be messing with human DNA, except for the rare case of trying to correct a genetic illness like cystic fibrosis. On the other hand, Cas13 could be the basis of a powerful new class of drugs that target RNA, particularly the type known as messenger RNA (mRNA), which is crucial to executing the business of the cell.
If DNA is the leather-bound manual containing all the instructions for how to operate a cell, mRNA is a flimsy photocopy of just the page that is needed at any one time on the factory floor.
Messenger RNA is a highly strategic target if you want to interfere with what a cancer cell is doing. For Fareh and his lab head Joe Trapani, Cas13 offered the chance to target the instructions that were helping cancer cells escape drug treatments.
Thats because Cas13 operates like scissors that snip away at the photocopied page of instructions represented by mRNA. Just which page is snipped is determined by a smart guide: a small, customisable piece of RNA that is able to seek out matching mRNA and is attached to the scissors. For every new page of mRNA instructions, a new guide could be quickly designed and attached.
In early tests, Cas13 was able to selectively destroy mRNA produced by the cancer cell lines. Buoyed by their success, Fareh and Trapani were embarking on a collaboration with the Childrens Cancer Institute in Sydney when COVID-19 struck. Like many researchers who were not mobilised to the COVID offensive, they had to down tools.
Until they realised: Cas13 could easily be adapted to fight SARS-CoV-2.
All that was needed was the genome sequence of the virus. Fareh had that by 10 January 2020, when the data was released by Chinese researchers led by Yong-Zhen Zhang at Fudan University, China who had isolated and fully sequenced the virus. (This was also the moment Moderna and Pfizer started designing their vaccines.)
What Fareh didnt have was a way to test the Cas13 scissors on the virus. But the Peter Mac is in striking distance of the Doherty Institute, the major nerve centre of Australias COVID response. So in May 2020 Fareh and Trapani walked across the road to chat with Doherty head, Sharon Lewin.
Within a week, Fareh and his lab had decked out the Cas13 scissors with a guide that could seek out the SARS-CoV-2 mRNA instructions for manufacturing the spike protein. This is the bit that gives the virus access to cells. Because the virus can mutate its spike, Farehs team used a computer to predict the least-changeable part of the spike mRNA instructions as their target.
Working with Lewins team, they tested the tool on SARS-CoV-2 growing in green monkey kidney cells and human lung cells in culture dishes.
Cas13 obliterated the spike protein message and stopped the virus from proliferating.
Better yet, the shifty virus could not easily evade Cas13. When Farehs team mutated the virus by introducing single letter changes, Cas13 with its attached RNA guide continued to seek and destroy them. The tipping point was when the virus accrued three mutations.
But vanquishing a virus in culture dishes is just the first step.
The next step is to test Cas13 in mice that have been bred to be susceptible to COVID-19. It will also be tested in infected human cells washed from the nose, and in infected lung organoids: mini organs grown from human stem cells.
A crucial issue is how to turn Cas13 into a drug. Cas13 itself is a protein, but its all-important guide is made of flimsy RNA.
This is where the Melbourne team plan to leverage off the global RNA revolution. Thirty years ago, the idea that RNA could be used as a drug was laughable. Its fragility was only the beginning researchers also knew that injecting large amounts of it could trigger dangerous immune reactions.
But dogged pioneers engineered workarounds, substituting the RNA code letter uridine for pseudouridine, an alternative naturally-occurring code letter, which calmed the stormy immune response. And to protect the RNA, they packaged it in fatty capsules known as lipid nanoparticles.
These are the steps the Melbourne team will not have to reinvent. But still, the question remains: how can Cas13 be delivered into the body?
A nasal spray, says Lewin.
Used early in the infection or as a preventive treatment, the spray could stop the virus gaining a foothold in nasal cells before it invades the lungs, where the real damage is done.
Lewins group already has years of experience packaging drugs in lipid nanoparticles, as part of a strategy to target drugs to reach the HIV virus hiding deep inside some cells. The team aims to use this technology to deliver Cas13, says Lewin.
Despite borrowing from the RNA revolution, theres no doubt that developing the Cas13 delivery technology will take years.
But more funding will speed its passage. To that end, Lewin has wasted no time, weaving together a collaboration of several Australian groups as well as those in Israel, the US and Denmark to submit a proposal to a US$3 billion fund for COVID antivirals announced by the Biden administration on 17 June 2021.
It may well take years for the first Cas13 antiviral nasal spray to run the gauntlet of development pipelines and prove itself in the clinic.
But it will take weeks for the second.
Well be ready for the next pandemic, says Fareh.
See the original post:
Learning from vaccines: the race to make antiviral drugs - Cosmos
- New Atlas of Rare Stem and Progenitor Cells Reveals New Cell Types - Inside Precision Medicine - March 28th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- GLP podcast: GE crops have lived up to the hype; Growing 'mini' organs from stem cells; How do we solve right-wing ... - Genetic Literacy Project - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Stem cells: past, present, and future - PMC - National Center for ... - March 19th, 2024
- Stem cells: a comprehensive review of origins and emerging clinical ... - March 19th, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 19th, 2024
- What are Stem Cells? - Types, Applications and Sources - BYJU'S - March 19th, 2024
- Stem Cell - The Definitive Guide | Biology Dictionary - March 19th, 2024
- Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth - Singularity Hub - March 19th, 2024
- Florida congresswoman sued the Pentagon over stem cells. One problem: her husband's stocks - Raw Story - January 23rd, 2024
- Can Stem Cells Improve Knee Pain or Are They A Waste of Money? - Bloomberg - January 23rd, 2024
- Stem cells used to successfully treat arthritis in gorilla at Budapest zoo - University of Sheffield News - January 23rd, 2024
- A computational model of stem cells' internal mechanism to recapitulate spatial patterning and maintain the self ... - Nature.com - January 23rd, 2024
- Advancing the generation of in-vivo chimeric lungs in mice using rat-derived stem cells - EurekAlert - January 6th, 2024
- 'I couldn't just give up on my dad' | Round Rock son donates stem cells to father battling leukemia - KVUE.com - January 6th, 2024
- Closing in on the ultimate quest to regenerate insulin in pancreatic stem cells - Medical Xpress - January 6th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 6th, 2024
- Regenerative Medicine and COPD: Generating Functional Lungs from Pluripotent Stem Cells - Medriva - January 6th, 2024
- What is a stem cell? YourGenome - December 2nd, 2023
- Stem cell transplant - NHS - December 27th, 2022
- Stem cells: a brief history and outlook - Science in the News - December 27th, 2022
- RUDN Physician And Russian Scientists Investigate Long-term Effects Of Treating Diabetic Ulcers With Stem Cells - India Education Diary - December 27th, 2022
- Stem Cell Basics | STEM Cell Information - National Institutes of Health - December 2nd, 2022
- Neural stem cell - Wikipedia - November 24th, 2022
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - November 24th, 2022
- Stem Cells- Definition, Properties, Types, Uses, Challenges - November 6th, 2022
- Brothers from Karnataka, Prapul and Prajwal donated their stem cells, save two blood cancer patients - APN News - November 6th, 2022
- Getting These Stem Cells Treatments: Crippled Ronnie Coleman Gives a Positive Update on His Ability to Walk - EssentiallySports - October 21st, 2022
- Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells - Cornell University The Cornell Daily Sun - October 13th, 2022
- Human neuron clusters transplanted into rats offer new tool to study the brain : Shots - Health News - NPR - October 13th, 2022
- The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion - Newswise - October 13th, 2022
- A $7 million grant to grow stem cell research - Swinburne University of Technology - October 13th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Management, Personalized Medicine, and Genome... - October 13th, 2022
- Brennand named Elizabeth Mears and House Jameson Professor of Psychiatry - Yale News - October 13th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - BioSpace - October 13th, 2022
- Stem Cells - alsa.org - October 4th, 2022
- Mouse embryo models built from stem cells take shape in a dish - Nature.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 4th, 2022
- Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem... - October 4th, 2022
- Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from... - October 4th, 2022
- Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma - Targeted Oncology - October 4th, 2022
- Hereditary E200K mutation within the prion protein gene alters human iPSC derived cardiomyocyte function | Scientific Reports - Nature.com - September 25th, 2022
- How To Eat Your Way to Better Health According to a Doctor - Eat This, Not That - September 25th, 2022
- Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz... - September 25th, 2022
- Types of blood cancer: Leukemia, lymphoma, and more - Medical News Today - September 25th, 2022
- September: er-blood | News and features - University of Bristol - September 25th, 2022
- Here Is Why You Heal Slower As You Age - Health Digest - September 25th, 2022
- Global Single Cell Analysis Market is Projected to Grow at a CAGR of 15.1% By 2032: Visiongain Reports Ltd - Yahoo Finance UK - September 25th, 2022
- Findings explain exceptional auditory abilities in Williams-Beuren Syndrome - EurekAlert - September 25th, 2022
- Finding the potency in planarians | Communications Biology - Nature.com - September 16th, 2022
- Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World... - September 16th, 2022
- Treating Cancer with Oncolytic Viruses - BioPharm International - September 16th, 2022
- Israel's Profuse Technology Raises $2.5M for Technology That Lowers Cost of Cultured Meat - The Spoon - September 16th, 2022
- Stem Cells Used to Grow Mouse Embryo - BioTechniques - September 8th, 2022
- Largest Gift in UCSD History to Fund Stem Cell Research on Space Station - Times of San Diego - September 8th, 2022
- Global Induced Pluripotent Stem Cells Market (2022 to 2027) - Growth, Trends, Covid-19 Impact and Forecasts - ResearchAndMarkets.com - Business Wire - September 8th, 2022
- Health on the Frontlines: The Healing Power of Stem Cells - Dans Papers - September 8th, 2022
- Top 3 grants in regenerative medicine: July 2022 - RegMedNet - September 8th, 2022
- Childhood leukemia treatment 2022: Where we are now and what it takes - EurekAlert - September 8th, 2022
- Treatment Choices for AML Were Increasingly Influenced by Immunological Responses - Physician's Weekly - September 8th, 2022
- BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 - StreetInsider.com - September 8th, 2022
- Global Recombinant Cell Culture Supplements Market Report 2022: Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines Presents... - September 8th, 2022
- CAR-T Beyond CGTs In Development In 2022 - BioProcess Online - September 8th, 2022
- ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell Islets for the Treatment of Type 1 Diabetes - Business Wire - September 8th, 2022
- Synthetic Mouse Embryo with Brain and Beating Heart Grown from Stem Cells - Genetic Engineering & Biotechnology News - August 30th, 2022
- Utilization of Modified Induced Pluripotent Stem Cells as the Advance | OPTH - Dove Medical Press - August 30th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - August 30th, 2022
- Brush Up: Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - August 30th, 2022
- Regenerative Properties of the Newborn Heart Offers Hope for Those With Congenital Heart Disease - The Epoch Times - August 30th, 2022
- Kanpur hospital is Indias first to perform fat-derived stem cell transplant for diabetic patients - India Today - August 30th, 2022
- Scientists Just Genetically Edited a Million Years of Evolution Into Mouse DNA - ScienceAlert - August 30th, 2022
- Canadian Blood Services Stem Cells for Life - August 22nd, 2022
- Scientists say they have created 'embryos' without sperm or eggs - Medical News Today - August 22nd, 2022
- Many stem cell lines used for research and therapies carry large number of mutations, Cambridge researchers find - Cambridge Independent - August 22nd, 2022
- Scientists hope to revive extinct mammal through stem cells and gene-editing in a first - The Mirror - August 22nd, 2022
- Stem cell therapy in capsule form - Malaya - August 22nd, 2022
- Cell Culture Technician Pluripotent Stem Cell Biology and Genome Editing job with UNIVERSITY OF SOUTHAMPTON | 305107 - Times Higher Education - August 22nd, 2022
- Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - The... - August 5th, 2022
- Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells - Newswise - July 27th, 2022